Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Report

Global and Region Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：149
  • REPORT CODE：GMM917979
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeuticsmarket, defines the market attractiveness level of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics industry, describes the types of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market and the development prospects and opportunities of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market in Chapter 13.

    By Player:

    • Astellas

    • Sanofi

    • Johnson & Johnson

    • Bayer

    By Type:

    • Hormonaltherapy

    • Chemotherapy

    • Immunotherapy

    • Radiotherapy

    By End-User:

    • Prostate Cancer

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption (2017-2022)

    • 7.2 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption (2017-2022)

    • 7.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption (2017-2022)

    • 7.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption (2017-2022)

    • 7.5 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption (2017-2022)

    • 7.6 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast (2022-2028)

    9 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Hormonaltherapy Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Chemotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Immunotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Radiotherapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Prostate Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Hormonaltherapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Radiotherapy Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Prostate Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Competitive Analysis

    • 14.1 Astellas

      • 14.1.1 Astellas Company Details

      • 14.1.2 Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service

    • 14.2 Sanofi

      • 14.2.1 Sanofi Company Details

      • 14.2.2 Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service

    • 14.3 Johnson & Johnson

      • 14.3.1 Johnson & Johnson Company Details

      • 14.3.2 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service

    • 14.4 Bayer

      • 14.4.1 Bayer Company Details

      • 14.4.2 Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

    • Figure Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Picture

    • Table Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption by Country (2017-2022)

    • Figure United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hormonaltherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Radiotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Prostate Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hormonaltherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prostate Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table Astellas (Foundation Year, Company Profile and etc.)

    • Table Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US